ENDRA Life Sciences (NDRA) Other Non-Current Liabilities (2024 - 2026)

ENDRA Life Sciences (NDRA) has reported Other Non-Current Liabilities for 3 consecutive years, with $555306.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 68.99% year-over-year to $555306.0 in Q2 2026; TTM through Jun 2026 was $555306.0, a 68.99% increase from a year earlier, with the FY2025 full-year figure at $479747.0, down 39.98% from the prior year.
• Other Non-Current Liabilities was $555306.0 for Q2 2026 at ENDRA Life Sciences, up from $488604.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $799284.0 in Q4 2024 and troughed at $328610.0 in Q2 2025.
• A 3-year average of $519736.7 and a median of $488604.0 in 2026 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities sank 39.98% in 2025 and surged 68.99% in 2026, its largest moves.
• Over 3 years, Other Non-Current Liabilities stood at $799284.0 in 2024, then slumped by 39.98% to $479747.0 in 2025, then rose by 15.75% to $555306.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $555306.0 (Q2 2026), $488604.0 (Q1 2026), and $479747.0 (Q4 2025), per Business Quant data.